Symposium: RECENT PROGRESS IN CANCER RESEARCH AND DEVELOPMENT OF NOVEL THERAPIES

Where: Ruth Hall, Faculty of Medicine, Bat Galim

 For registration click here

Scientific Program

Monday, 21.11.16
08:45 – Introduction, Dean Eliezer Shalev, Eyal Gottleib

Session A: What Went Wrong – Fundamentals of Cancer Signaling: Chair – Asya Rolls
09:00 – 09:35 Douglas Hanahan, Ecole Polytechnique Federale De Lausanne
Mechanistic insights into multistep tumorigenesis and its (evolutionary) adaptations
09:35 – 10:10 Gad Getz, Broad Institute of MIT and Harvard
10:10 – 10:45 Adi Kimchi, Weizmann Institute of Science
The protein interaction map of autophagy and apoptosis: from basic principles to a therapeutic vision

10:45 – 11:10 Coffee Break

Session A: Continued: Chair – Ruth Hershberg
11:10 – 11:45 Uri Alon, Weizmann Institute of Science
Evolutionary Tradeoffs and the Geometry of Phenotype Space
11:45 – 12:20 Roy Kishoni, Technion
12:20 – 12:55 Carlos Caldas, Cambridge Cancer Centre
Modelling Breast Cancer Inter- and Intra-Tumor Heterogeneity Using Patient-Derived Explants

13:00 – 14:30 Lunch

Session B: Cancer Metabolism: Chair – Tomer Shlomi
14:30 – 15:05 Lewis Cantley, Meyer Cancer Center, Cornell University
PI 3-Kinase and Cancer Metabolism
15:05 – 15:40 Celeste Simon, University of Pennsylvania
Striking a Balance between Cellular Growth and Homeostasis
15:40 – 16:15 Eyal Gottlieb, TICC, Faculty of Medicine, Technion
Targeting Metabolic Vulnerabilities of Succinate Dehydrogenase Deficient Tumours

16:15 – 16:40 Coffee Break

Session C: Proteostasis: Chair: Shenhav Cohen
16:40 – 17:15 Nahum Sonenberg, McGill University, Montreal
Translational control of cancer by eIF4E via the mTOR and MAPK pathways
17:15 – 17:50 Amir Orian, TICC, Faculty of Medicine, Technion
Specification and maintenance of differentiated cell identity
17:50 – 18:25 Ze’ev Ronai, Co-Director TICC, Faculty of Medicine, Technion
RNF5 in ER stress and cancer development
18:25 – 19:00 Aaron Ciechanover, Co-Director TICC, Faculty of Medicine, Technion
Monoubiquitination as a Novel Proteasomal Degradation Signal: Mechanistic and Biomedical Implications

Tuesday, 22.11.2016

Session D: Rewired DNA Damage signaling: Chair – Reut Shalgi
09:00 – 09:35 Yosef Shiloh, Sackler School of Medicine, Tel Aviv University
The DNA damage response: a matter of checks and balances
09:35 – 10:10 Varda Rotter, Weizmann Institute of Science
Can mutant p53 change faces into a genome guardian?
10:10 – 10:45 Moshe Oren, Weizmann Institute of Science
Opposing Effects of RNF20 and Histone H2B Ubiquitylation In Basal-Like Versus Luminal Breast Cancer

10:45 – 11:10 Coffee Break

Session E: Microenvironment: Chair – Yoni Savir
11:10 – 11:45 Michael Karin, University of California, San Diego
Metabolic and Immune Control of Liver Tumorigenesis- From Etiology to Treatment
11:45 – 12:20 Eli Pikarsky, Faculty of Medicine, The Hebrew University of Jerusalem
Ectopic Lymphoid Structures Function as Microniches for Tumor Progenitor Cells in HCC
12:20 – 12:55 Yosef Yarden, Weizmann Institute of Science
Playing Chess Against EGFR-driven Lung Cancer
12:55 – 13:30 Shai Shen-Orr, TICC, Faculty of Medicine, Technion
Equal Protection? Exploring Immune System Variation

13:30-14:45 Lunch

Session F: From Bench to Bedside: Chair – Yehuda Chowers
14:45 – 15:20 Gad Rennert, TICC, Faculty of Medicine, Technion
Genomic cancer medicine
15:20 – 15:55 Yuval Shaked, TICC, Faculty of Medicine, Technion
The Yin and Yang Effects of Cancer Therapy
15:55 – 16:30 Avigdor Scherz, Weizmann Institute of Science
TOOKAD® Soluble VTP: From Local Tumor Ablation to Systemic Cancer Control
16:30 – 17:05 Uri Sivan, TICC, Russell Berrie Nanotechnology Institute, Technion
A Viable Route to a Massively Parallel Analysis of Individual Cells Extracted from a Tumor

17:05 – 17:30 Coffee Break

Session G: Novel Approaches for Targeting Cancer: Chair – Ron Epelbaum
17:30 – 18:05 Kevan Shokat, Department of Cell. and Mol. Pharmacology, UCSF
Chemical Strategies for Drugging Undruggable Targets in Oncology
18:05 – 18:40 Yinon Ben Neriah, Faculty of Medicine, The Hebrew University of Jerusalem
CKIa as a therapeutic target in cancer
18:40 – 19:15 Keith Flaherty, Dana-Farber/ Harvard Cancer Center
Bringing precision medicine principles to epigenetic states in melanoma

19:15 – Closing Remarks (Ze’ev Ronai / Hagit Attya)